Solid Lipid Nanoparticles as Delivery Systems for Bromocriptine
- 669 Downloads
The present investigation describes a formulative study for the development of innovative drug delivery systems for bromocriptine.
Solid lipid nanoparticles (SLN) based on different lipidic components have been produced and characterized. Morphology and dimensional distribution have been investigated by electron microscopy and Photon Correlation Spectroscopy. The antiparkinsonian activities of free bromocriptine and bromocriptine encapsulated in nanostructured lipid carriers were evaluated in 6-hydroxydopamine hemilesioned rats, a model of Parkinson’s disease.
Tristearin/tricaprin mixture resulted in nanostructured lipid carriers with stable mean diameter up to 6 months from production. Bromocriptine was encapsulated with high entrapment efficiency in all of the SLN samples, particularly in the case of tristearin/tricaprin mixture. Bromocriptine encapsulation did not change nanoparticle dimensions. In vitro release kinetics based on a dialysis method demonstrated that bromocriptine was released in a prolonged fashion for 48 h. Tristearin/tricaprin nanoparticles better controlled bromocriptine release. Both free and encapsulated bromocriptine reduced the time spent on the blocks (i.e. attenuated akinesia) in the bar test, although the action of encapsulated bromocriptine was more rapid in onset and prolonged.
It can be concluded that nanostructured lipid carriers encapsulation may represent an effective strategy to prolong the half-life of bromocriptine.
Key wordsbar test bromocriptine (BK) cryo transmission electron microscopy nanostructured lipid carrier (NLC) photon correlation spectroscopy (PCS) solid lipid nanoparticles (SLN)
Authors are grateful to Dr. Fabrizio Bortolotti (University of Ferrara) for HPLC technical assistance. This work was supported by Regione Emilia Romagna, Spinner Project.
- 2.K. Westesen and B. Siekmann. Biodegradable colloidal drug carrier systems based on solid lipids. In S. Benita (ed.), Microencapsulation, Marcel Dekker, New York, 1996, pp. 213–258.Google Scholar
- 10.J. Temsamani, J. M. Scherrmann, A. R. Rees, and M. Kaczorek. Brain drug delivery technologies: novel approaches for transporting therapeutics. PSTT. 3:2000 (2000).Google Scholar
- 27.M. Marti, F. Mela, M. Fantin, S. Zucchini, J.M. Brown, J. Witta, M. DiBenedetto, B. Buzas, R.K. Reinscheid, S. Salvadori, R. Guerrini, P. Romualdi, S. Candeletti, M. Simonato, B.M. Cox, and M. Morari. Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson’s disease. J Neurosci. 95:9591–9601 (2005).CrossRefGoogle Scholar
- 28.G. Paxinos and C. Watson. The rat brain in stereotaxic coordinates. Ed. Academic, Sydney (1982).Google Scholar
- 32.K. Jores, W. Mehnert, M. Drechsler, H. Bunjes, C. Johann, and K. Maeder. Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. J. Control. Release. 95:217–227 (2004).PubMedCrossRefGoogle Scholar
- 37.Z.R. Zhang, J.X. Wang, and J. Lu. Optimization of the preparation of 30,50-dioctanoyl-5-fluoro-20-deoxyuridine pharmacosomes using central composite design. Acta Pharmaceutica Sinica. 36:461–465 (2001).Google Scholar
- 38.Y.X. Peng, Y.L. Zhuang, and G.T. Liao. Study on bone marrow targeting daunorubicin polybutylcyanoacrylate nanoparticles. Chin. J. Pharm. 31:57–61 (2000).Google Scholar
- 40.P. Calvo, B. Gouritin, H. Villarroya, F. Eclancher, C. Giannavola, C. Klein, J.P. Andreux, and P. Couvreur. Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. Eur. J. Neurosci. 15:1317–1326 (2002).PubMedCrossRefGoogle Scholar
- 43.J.M. Koziara, P.R. Lockman, D.D. Allen, and R.J. Mumper. In situ blood-brain barrier transport of nanoparticles. Pharm. Res. 20:1772–1778 (2003).Google Scholar